BACKGROUND: This study aimed to address long-term survival in a large population-based cohort of men with prostate cancer receiving radical prostatectomy compared to other treatments. METHODS: We studied 5,845 patients diagnosed with local/regional stage prostate cancer at age 65-74 in 1992 with comorbidity score <2, who were defined as potential candidates for radical prostatectomy and identified from the SEER (Surveillance, Epidemiology and End Results)-Medicare cohort with median follow-up of 11 years. RESULTS: Of 5,845 patients, 10-year all-cause survival rates were the highest for patients receiving radical prostatectomy (81.0%; 95% CI: 79.4-82.4%), followed by radical prostatectomy in combination with radiotherapy (67.6%; 62.0-72.5%), radiotherapy (60.5%; 58.3-62.6%), and were the lowest for watchful-waiting (50.7%; 47.5-53.8%). A similar pattern was found for 10-year prostate cancer-specific survivals by treatments. After adjusting for age, ethnicity, region, Gleason Score, comorbidity, median annual household income, hormone therapy and chemotherapy, the hazard ratio of all-cause mortality was 0.31 (95% CI: 0.25-0.37) for radical prostatectomy and 0.38 (95% CI: 0.28-0.52) for radical prostatectomy plus radiation therapy compared to those with watchful-waiting. CONCLUSIONS: There was a significant long-term survival benefit in men receiving radical prostatectomy compared to those receiving watchful-waiting or radiotherapy.
BACKGROUND: This study aimed to address long-term survival in a large population-based cohort of men with prostate cancer receiving radical prostatectomy compared to other treatments. METHODS: We studied 5,845 patients diagnosed with local/regional stage prostate cancer at age 65-74 in 1992 with comorbidity score <2, who were defined as potential candidates for radical prostatectomy and identified from the SEER (Surveillance, Epidemiology and End Results)-Medicare cohort with median follow-up of 11 years. RESULTS: Of 5,845 patients, 10-year all-cause survival rates were the highest for patients receiving radical prostatectomy (81.0%; 95% CI: 79.4-82.4%), followed by radical prostatectomy in combination with radiotherapy (67.6%; 62.0-72.5%), radiotherapy (60.5%; 58.3-62.6%), and were the lowest for watchful-waiting (50.7%; 47.5-53.8%). A similar pattern was found for 10-year prostate cancer-specific survivals by treatments. After adjusting for age, ethnicity, region, Gleason Score, comorbidity, median annual household income, hormone therapy and chemotherapy, the hazard ratio of all-cause mortality was 0.31 (95% CI: 0.25-0.37) for radical prostatectomy and 0.38 (95% CI: 0.28-0.52) for radical prostatectomy plus radiation therapy compared to those with watchful-waiting. CONCLUSIONS: There was a significant long-term survival benefit in men receiving radical prostatectomy compared to those receiving watchful-waiting or radiotherapy.
Authors: Leah Y Nakamura; Rafael N Nunez; Paul E Andrews; Robert G Ferrigni; Mitchell R Humphreys; Scott K Swanson; Christopher E Wolter; Erik P Castle Journal: J Robot Surg Date: 2011-02-05
Authors: Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben Journal: Cochrane Database Syst Rev Date: 2020-06-04
Authors: Ethel C Garnier-Amblard; Suzanne G Mays; Richard F Arrendale; Mark T Baillie; Anatoliy S Bushnev; Deborah G Culver; Taylor J Evers; Jason J Holt; Randy B Howard; Lanny S Liebeskind; David S Menaldino; Michael G Natchus; John A Petros; Harsha Ramaraju; G Prabhakar Reddy; Dennis C Liotta Journal: ACS Med Chem Lett Date: 2011-03-25 Impact factor: 4.345
Authors: Marco Bandini; Raisa S Pompe; Michele Marchioni; Zhe Tian; Giorgio Gandaglia; Nicola Fossati; Derya Tilki; Markus Graefen; Francesco Montorsi; Shahrokh F Shariat; Alberto Briganti; Fred Saad; Pierre I Karakiewicz Journal: World J Urol Date: 2017-10-23 Impact factor: 4.226
Authors: Judd W Moul; Hans Lilja; O John Semmes; Raymond S Lance; Robert L Vessella; Martin Fleisher; Clarisse Mazzola; Mark J Sarno; Barbara Stevens; Robert E Klem; Jonathan E McDermed; Melissa T Triebell; Thomas H Adams Journal: Urology Date: 2012-10-26 Impact factor: 2.649
Authors: Kenneth G Nepple; Andrew J Stephenson; Dorina Kallogjeri; Jeff Michalski; Robert L Grubb; Seth A Strope; Jennifer Haslag-Minoff; Jay F Piccirillo; Jay P Ciezki; Eric A Klein; Chandana A Reddy; Changhong Yu; Michael W Kattan; Adam S Kibel Journal: Eur Urol Date: 2013-03-13 Impact factor: 20.096